Korean Circ J.  2022 Nov;52(11):808-813. 10.4070/kcj.2022.0256.

Preparations for the Assessment of COVID-19 Infection and Long-Term Cardiovascular Risk

• Jung J

• KMID: 2534900
• DOI: http://doi.org/10.4070/kcj.2022.0256

Abstract

Studies showing that coronavirus disease 2019 (COVID-19) is associated with an increased risk of cardiovascular disease continue to be published. However, studies on how long the overall cardiovascular risk increases after COVID-19 and the magnitude of its long-term effects have only been confirmed recently. This is partly because the distinction between cardiovascular risk as an acute complication of COVID-19 or post-acute cardiovascular manifestations is ambiguous. Long-COVID has arisen as an important topic in the second half of the pandemic. This term indicates that symptoms persist for more than two 2 months; following three months of SARS-CoV-2 infection and cannot be explained by other medical conditions. Despite the agreement of these international organizations and experts, it is difficult to define whether there is sufficient medical evidence to prove the existence of longCOVID. However, the Korean government and Korea Disease Control and Prevention Agency (KDCA) are preparing a new platform to assess the long-term impact of COVID-19. Using this data, a prospective cohort of 10,000 confirmed COVID-19 cases will be established. This cohort will be linked with claims data from the National Health Insurance Services (NHIS) and it is expected that increased real-world evidence of long-COVID will be accumulated.

Keyword

COVID-19; Long-COVID; COVID-19 vaccination; Cardiovascular risk

Figure

• 

  Figure 1 The concept of Korean COVID-19 big-data platform. CDM = Common Data Model; COVID-19 = coronavirus disease 2019; KDCA = Korea Disease Control and Prevention Agency; NHIS = National Health Insurance Services.

Reference

1. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018; 378:345–353. PMID: 29365305.

2. Barnes M, Heywood AE, Mahimbo A, Rahman B, Newall AT, Macintyre CR. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Heart. 2015; 101:1738–1747. PMID: 26310262.

3. Merkler AE, Parikh NS, Mir S, et al. Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza. JAMA Neurol. 2020; 77:1366–1372.

4. National Institute for Health and Care Excellence. NICE guideline [NG188]. COVID-19 rapid guideline: managing the long-term effects of COVID-19 [Internet]. London: National Institute for Health and Care Excellence;2020. 12. 18. Available from: https://www.nice.org.uk/guidance/ng188 .

5. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus [Internet]. Geneva: World Health Organization;2021. 10. 06. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 .

6. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009; 9:601–610. PMID: 19778762.

7. Bae JW. Delay or giving up of influenza vaccination induced by unscientific journalism makes influenza outbreak and its subsequent cardiovascular death surges especially in elderly. J Korean Med Sci. 2020; 35:e385. PMID: 33140594.

8. Kim YE, Huh K, Park YJ, Peck KR, Jung J. Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection. JAMA. 2022; 328:887–889. PMID: 35867050.

9. National Academy of Medicine of Korea, COVID-19 Vaccine Safety Committee. Vaccine Safety Report. Seoul: National Academy of Medicine of Korea;2022.